Evidence map›Paper›PMID 39801009›Full record

ArticleClinical and translational medicine2025

Translational inhalable extracellular vesicle-based mRNA therapy for the treatment of lung cancer.

Mengrui Liu, Brian Henick, Ke Cheng

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mengrui LiuDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.
Brian HenickHerbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA.
Ke ChengDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.ORCID https://orcid.org/0000-0001-8053-7059

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Targeted Nanoparticles for Stem Cell Redirecting and Regenerative MedicineR01HL123920 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2015 to 2023
$4.8M
Harnessing Platelet-Endothelial Interactions for Stem Cell DeliveryR01HL144002 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Ke Cheng · 2019 to 2026
$4.5M
Novel surface-modified bioresorbable zinc-based stent materialsR01HL140562 · NHLBI · UNIVERSITY OF NORTH TEXAS · PI Ke Cheng, Donghui Zhu · 2018 to 2026
$4.3M
Modulating Exosome Cargos and Surfaces for Precision Heart RepairR01HL146153 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Ke Cheng · 2019 to 2026
$4.2M
Drug Delivery and Biomimetic Approaches for Optimal Stem Cell TherapyR01HL154154 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2021 to 2024
$3.1M
Surgical Microneedle Patch Delivery of CMMP for Heart RepairR01HL149940 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2020 to 2023
$3.0M
Cardiac Patches Loaded with Stem Cell Factors to Treat Heart FailureR01HL147357 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2019 to 2022
$2.7M
Inhalable stem cell exosome therapy for cardiac injuryR01HL170612 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Ke Cheng · 2024 to 2026
$2.2M
Enhancing vascular delivery of stem cells and microparticlesR01HL137093 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2017 to 2020
$1.5M
NCI NIH HHS P30 CA013696NHLBI NIH HHS R01 HL123920NHLBI NIH HHS R01 HL137093NHLBI NIH HHS R01 HL140562NHLBI NIH HHS R01 HL144002NHLBI NIH HHS R01 HL146153NHLBI NIH HHS R01 HL147357NHLBI NIH HHS R01 HL149940NHLBI NIH HHS R01 HL154154NHLBI NIH HHS R01 HL170612NIH HHS HL123920NIH HHS HL137093NIH HHS HL144002NIH HHS HL146153NIH HHS HL147357NIH HHS HL 149940NIH/NCI Cancer Center Support P30CA013696
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39801009
PMCPMC11726640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.